GHRP-2

GHRP-2 is a synthetic peptide that mimics the action of ghrelin, a hormone your body produces to signal hunger and stimulate growth hormone release. It binds to the ghrelin receptor (GHS-R1a) in the pituitary gland, prompting a rapid pulse of growth hormone (GH) into the bloodstream. This property makes it a valuable tool for researchers studying pituitary function and for clinicians diagnosing GH deficiency Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Unlike direct GH injections, GHRP-2 does not supply GH; it coaxes the pituitary to release its own stores. The resulting GH pulse is short-lived, so research protocols typically use multiple daily doses to mimic the body's natural pulsatile rhythm Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. While its best-documented use is as a diagnostic test in Japan, GHRP-2 has also been investigated for appetite stimulation, tendon-bone healing, and anti-inflammatory effects, though most of this evidence comes from animal or cell studies Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model+3.

GHRP-2’s main action is straightforward: it activates the ghrelin receptor (GHS-R1a) on somatotroph cells in the anterior pituitary, triggering those cells to release growth hormone Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. This mechanism runs parallel to the GHRH pathway, which is why GHRP-2 can still produce a strong GH pulse even when GHRH signaling is impaired Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

In clinical testing, researchers administer a fixed dose (typically 100 μg intravenously) and measure GH levels over the next 30–120 minutes. A robust response indicates that the pituitary’s GH reserves are intact; a blunted response often points to deeper hypothalamic-pituitary dysfunction Two siblings with Schaaf-Yang syndrome treated with growth hormone+2. In Japan, a peak GH ≤9 ng/mL after GHRP-2 is commonly used to define severe adult GH deficiency Pituitary dysfunction in trans-sellar encephalocele: a two-case report and a literature review+1.

Beyond GH release, GHRP-2 also stimulates the ACTH → cortisol axis to a measurable degree. This makes it useful for screening secondary adrenal insufficiency in patients with pituitary disorders Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure+1. In animal and cell models, it reduces M1 macrophage activity and lowers inflammatory signaling, suggesting additional immunomodulatory roles Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model+1.

Growth Hormone Stimulation

GHRP-2 is a potent provocateur of GH release. In adolescents without organic pituitary damage, peak GH levels can exceed 80 ng/mL after a single 100 μg dose, far above the cut-off for severe deficiency Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis+1. The size of the response depends on the health of the pituitary: those with genetic or structural damage show very little GH rise, while healthy volunteers see robust spikes Two siblings with Schaaf-Yang syndrome treated with growth hormone+1.

Appetite Increase

Because it acts through the ghrelin receptor, GHRP-2 reliably increases hunger. In a controlled trial, single doses boosted food intake in healthy men Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. This orexigenic effect has been explored as a potential therapy for cachexia and anorexia nervosa, with one case report showing improved body weight after a year of intranasal use One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient.

Tissue Repair (Preclinical)

In a rat rotator cuff tear model, GHRP-2 improved tendon-bone healing: it reduced pro-inflammatory M1 macrophages, increased bone density, and enhanced biomechanical strength Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model. Human trials for orthopedic recovery are not yet available.

Endocrine Utility

Combined GH and ACTH responses make GHRP-2 a useful dynamic test for broader pituitary reserve. Low cortisol peaks during the test can help identify hidden adrenal insufficiency in patients with hypothalamic-pituitary disease Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure+2.

Anti-inflammatory and other effects

Cell studies show GHRP-2 can dampen inflammatory signaling in human granulosa cells via p38/JNK/NF-κB pathways Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells. Animal work also points to supraspinal pain relief through opioid-linked mechanisms Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice.

Because GHRP-2 is primarily used as an acute diagnostic agent, long-term treatment protocols are not standardized in the literature. Instead, research protocols for non-diagnostic aims are extrapolated from pharmacodynamics and community practice Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Typical Research Dosing Most published studies use a single 100 μg intravenous dose for stimulation testing. For repeated administration (e.g., to study chronic GH release), protocols generally use subcutaneous injections of 100–300 μg, one to three times daily, timed away from meals to avoid insulin blunting of the GH response Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. A common starting point is 100 μg twice daily, with the first dose on an empty stomach in the morning and the second before bed.

Route Choices

• Subcutaneous injection is the default for research because it provides reliable absorption without medical supervision. Practitioner consensus favors this route.
• Intravenous is the clinical standard for diagnostic tests, producing an immediate and maximal GH peak Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure+1.
• Intranasal use is biologically active: detection studies show urinary excretion for up to 47 hours after nasal dosing Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin+1. However, chronic efficacy data via this route are scarce.

Duration and Cycling Without long-term human trials, practitioners often cycle GHRP-2 to avoid tolerance and side-effect accumulation. Common cycles last 4–12 weeks, followed by a 2–4 week break, or a 5-days-on/2-days-off pattern is employed. Community protocols inform these practices.

GHRP-2 arrives as a lyophilized powder requiring reconstitution before use. Because it is a delicate peptide, careful handling preserves bioactivity.

Which Diluent to Use Bacteriostatic water is preferred for multi-dose vials because it inhibits bacterial growth. Sterile water for injection works if the solution will be used quickly. These are community protocol standards.

Mixing Slowly inject the diluent down the side of the vial and swirl gently. Do not shake, as foaming can degrade the peptide and cause inaccurate dosing Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+2. A dilution yielding 1 mg/mL (e.g., 5 mg in 5 mL) gives a handy concentration: 10 units (0.1 mL) on a U-100 insulin syringe delivers 100 μg, the most common research dose.

Storage

• Unopened vial: Keep in the refrigerator (2–8 °C) for weeks to months. For longer storage, freeze at –20 °C.
• Reconstituted solution: Store in the fridge and use within 14–30 days. Discard if it becomes cloudy or contains particles.
• Avoid freeze‑thaw: Repeated temperature swings accelerate breakdown; aliquot the solution into single-use portions if you plan to store it frozen.

All dose calculations are handled by the interactive calculator on this page.

GHRP-2’s effects can shift when paired with other compounds. Researchers and practitioners report several notable interactions.

Synergistic Combinations

• GHRH analogs (CJC-1295, sermorelin): Because GHRP-2 and GHRH analogs stimulate GH via separate receptors, combining them produces a larger GH pulse than either alone. Clinical studies show this synergy, though long-term outcome data are sparse Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis+1.
• Corticosteroids: Some clinical data show that GH response to GHRP-2 is preserved during corticosteroid therapy, though alterations in ACTH/cortisol dynamics may still occur. Monitor endocrine parameters if used concurrently Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure+1.

Antagonistic or Cautionary Pairs

• GLP-1 agonists (semaglutide, tirzepatide): These suppress appetite, opposing GHRP-2’s orexigenic effect. The net impact on body composition is unpredictable.
• Insulin or insulin sensitizers: Agents that lower free fatty acids (e.g., acipimox) can enhance GHRP-2’s GH response Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men, while insulin resistance generally dulls it. Glucose control should be monitored.
• Neuroactive drugs: GHRP-2 showed supraspinal antinociception via opioid receptors in animals Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice, so additive effects with opioids or sedatives are possible, though human studies are absent.

Peptide Redundancy Stacking multiple ghrelin agonists (e.g., GHRP-2 + ipamorelin + MK-677) is unlikely to add benefit and may worsen hunger, fluid retention, and receptor desensitization. This is based on community protocol.

As a receptor agonist, GHRP-2 can lose subjective effectiveness with continuous use. Although the pituitary’s GH stores do not empty, some users report diminishing hunger and GH-related effects after several weeks, suggesting receptor adaptation Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Common Cycling Patterns

• Short cycles: 4–8 weeks on, followed by 2–4 weeks off.
• Longer cycles: 8–12 weeks on, with a 4-week break.
• Weekly pulse cycling: administer on 5 consecutive days, then 2 days off each week.

These patterns are drawn from practitioner consensus rather than controlled trials. The rationale is to prevent tachyphylaxis and to limit side effects like excessive appetite, water retention, and elevated cortisol Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure+1.

When to Consider a Break

• If the appetite boost becomes disruptive or leads to uncontrolled calorie intake.
• If signs of fluid retention (puffy face, swollen fingers) or lethargy persist.
• If fasting glucose or IGF-1 levels climb outside the desired range.
• If sleep is disturbed, with vivid dreams or a “wired‑tired” feeling.

Because GHRP-2 is detectable in urine for roughly 47 hours after use, athletes should plan breaks around testing windows if applicable On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse+1.

Stacking GHRP-2 with complementary peptides is common practice to fine-tune GH output or to target multiple pathways. The evidence base for these combinations varies.

GHRP-2 + CJC-1295 (or Mod GRF 1‑29) This is the classic dual‑secretagogue stack. GHRP-2 hits the ghrelin receptor while CJC-1295 (a GHRH analog) stimulates a separate GHRH receptor on the same pituitary cell. Together they produce a synergistic GH pulse that is larger and more natural than either alone Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis+1. Typical research doses are 100 μg of each, injected subcutaneously up to three times daily on an empty stomach.

GHRP-2 + BPC-157 / TB‑500 For soft‑tissue and tendon healing, researchers sometimes pair GHRP-2 with repair peptides. Preclinical data show GHRP-2 improves tendon‑bone healing in rats Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model, and BPC‑157 has well‑known healing properties. Human outcome data for this stack are unavailable.

GHRP-2 + Ipamorelin or MK‑677 Because GHRP‑2 and ipamorelin both target the ghrelin receptor, combining them is typically redundant. MK‑677, an oral ghrelin agonist, is longer‑acting; if used together, the total ghrelin drive may be excessive, increasing hunger and water retention [community protocol].

Avoid Stacking with GH or IGF‑1 Analogs Adding exogenous GH while using a secretagogue dysregulates feedback loops and may increase side‑effect risk without clarifying effect attribution. Such stacks require specialist oversight [practitioner consensus].

GHRP-2 is not approved by the FDA as a therapeutic. It is used clinically in Japan for GH stimulation testing, but in most countries it falls under the category of an investigational or research‑only peptide Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Anti‑Doping Status GHRP‑2 is prohibited at all times by the World Anti‑Doping Agency (WADA) as a peptide hormone and releasing factor. Detection methods are robust: after intranasal use, parent compound and metabolites can be found in urine for up to 47 hours, and dried blood spot tests are also effective On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse+3. Supplement contamination is a real concern; GHRP‑2 has been identified in products sold as dietary supplements, meaning even unsuspecting consumers could test positive Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport+1.

Legal Landscape

• United States: Not an FDA‑approved drug; possession may be illegal if sold as a supplement or unapproved new drug. It is not listed as a controlled substance, but its sale is restricted Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.
• International: Japan recognizes GHRP‑2 as a diagnostic agent, but elsewhere it is typically unregistered. Importation can result in seizure by customs.
• Athletes: Any use violates anti‑doping rules and carries significant career and legal risks.

GHRP‑2 has been administered to hundreds of patients in clinical testing, providing a reasonable profile of acute safety. The most common acute effects are hunger, facial flushing, lightheadedness, and temporary fatigue Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. These usually resolve within an hour of dosing.

HPA‑Axis Effects Because GHRP‑2 can nudge ACTH and cortisol upward, people with underlying pituitary or adrenal disease may experience atypical stress responses. In one study, nearly half the patients with hypothalamic‑pituitary disorders had undiagnosed secondary adrenal insufficiency that the GHRP‑2 test helped reveal Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. Unmasking such a condition through self‑experimentation could be dangerous; medical workup is advised if symptoms like persistent fatigue, dizziness, or hyponatremia appear.

Metabolic Considerations Repeated GH surges can raise IGF‑1 levels, which may promote insulin resistance and fluid retention. Monitoring fasting glucose and IGF‑1 every 4–8 weeks is prudent. Community protocols suggest this frequency. Edema, hand tingling, and increased blood pressure are signs to pause or reduce dosing.

Long‑term Unknowns No multi‑year safety studies exist for GHRP‑2 used outside diagnostic settings. Theoretical risks include accelerated growth of hormone‑sensitive tumors and disruption of fertility due to ghrelin’s role in reproductive physiology Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Pregnant or breastfeeding individuals should avoid GHRP‑2 entirely.

Injection Site Subcutaneous administration can cause redness, itching, or bruising. Rotating sites and using sterile technique minimize these issues, as advised by practitioner consensus.